These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 3485265)

  • 1. [Ceftriaxone in the therapy of infections of the lower respiratory tract: comparison with cefotaxime].
    Lanni N; Scaglione B
    Minerva Med; 1986 Mar; 77(9-10):317-9. PubMed ID: 3485265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roxithromycin (RU 28965) in the treatment of respiratory tract infections.
    Grassi C; Bertoletti R; De Rose V; Manara G; Mangiarotti P
    Chemioterapia; 1987 Feb; 6(1):41-4. PubMed ID: 3103931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E; Dalhoff A; Korfmann G
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical evaluation of ceftriaxone in treating lower respiratory tract infections.
    Abbate GF; Alagia I; Giaquinto E; Leonessa V; Caputi M; Guarino C; Micillo E; Catena E; Altucci P
    Chemioterapia; 1986 Feb; 5(1):26-32. PubMed ID: 3955779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of ceftriaxone.
    File TM; Tan JS; Salstrom SJ
    Clin Ther; 1984; 6(5):653-61. PubMed ID: 6090021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multicentre, randomized, prospective and comparative study of ceftriaxone, cefotaxime and cefuroxime in treating mild to moderate respiratory tract infection].
    Gao B; Hu J; Deng W
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Sep; 21(9):528-31. PubMed ID: 11360502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of cefodizime, cefuroxime, ceftriaxone against respiratory pathogens.
    Paniara O; Platsouka E; Dimopoulou H; Constantoulaki S
    J Chemother; 1994 Feb; 6(1):35-8. PubMed ID: 8071676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of once-daily cephalosporin regimens for community-acquired lower respiratory tract infections in patients with chronic lung disease.
    McCabe RE; Schlossberg D; Donowitz GR; Scheld WM; Zellner SR; Lindenberg LB; Armstrong JH; Ein ME
    Clin Ther; 1989; 11(3):304-14. PubMed ID: 2663160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of cefixime in pediatric respiratory tract infections].
    Iwai N; Nakamura H; Kasai K; Ozaki T; Matsui Y; Tauchi N; Yamaguchi H; Taneda Y; Maki T
    Jpn J Antibiot; 1991 Jan; 44(1):35-47. PubMed ID: 2041146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cefotaxime in bronchopulmonary infections (author's transl)].
    Kermarec J; Sauvaget J
    Nouv Presse Med; 1981 Feb; 10(8):650-3. PubMed ID: 6259612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nosopharyngeal microflora in ambulatory treated children and adults with upper respiratory tract infections].
    Zientara M; Rudy M; Nowakowska M; Martirosian G
    Med Dosw Mikrobiol; 2006; 58(3):239-45. PubMed ID: 17340999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bacterial infectious agents implicated in lower respiratory tract infections in general practice].
    Vernejoux JM; Texier-Maugein J; Rio P; Guizard AV; Tunon de Lara JM; Taytard A
    Rev Pneumol Clin; 1997; 53(3):138-43. PubMed ID: 9296114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial effects of Eucalyptus globulus leaf extract on pathogenic bacteria isolated from specimens of patients with respiratory tract disorders.
    Salari MH; Amine G; Shirazi MH; Hafezi R; Mohammadypour M
    Clin Microbiol Infect; 2006 Feb; 12(2):194-6. PubMed ID: 16441463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory infections: clinical evaluation.
    Grassi C
    Clin Ther; 1985; 7 Suppl A():45-54. PubMed ID: 3907845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International experiences with ceftriaxone in the treatment of lower respiratory tract infections.
    Grassi C; Mangiarotti P
    Chemioterapia; 1987 Oct; 6(5):364-73. PubMed ID: 3322589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative evaluation of the in vitro and in vivo antibacterial activity of ceftriaxone and piperacillin: determination of the inhibitory quotient in bronchial secretions].
    Fraschini F; Scaglione F; Ripamonti L; Cogo R; Casali W
    Recenti Prog Med; 1988 May; 79(5):224-9. PubMed ID: 3051198
    [No Abstract]   [Full Text] [Related]  

  • 19. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies.
    Gums JG; Boatwright DW; Camblin M; Halstead DC; Jones ME; Sanderson R
    Ann Pharmacother; 2008 Jan; 42(1):71-9. PubMed ID: 18094350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefodizime once daily in the treatment of lower respiratory tract infections.
    Piovano CF; Palombini BC; Dagrosa EE; Mendoza F; Facco EB
    Arzneimittelforschung; 1997 May; 47(5):674-7. PubMed ID: 9205786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.